-
Investors who purchased shares of Fate Therapeutics, Inc. (NASDAQ: FATE) and currently hold any of those NASDAQ: FATE shares have certain options and should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
An investigation on behalf of investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) was announced over potential breaches of fiduciary duties by certain officers and directors at Fate Therapeutics, Inc.
The investigation by a law firm concerns whether certain Fate Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Shares of Fate Therapeutics, Inc. grew from $1.48 per share in May 2016 to as high as $14.03 per share in February 2018.
